



S&S Healthcare Holding Ltd.

(Original name : Swissray Global Healthcare Holding Ltd.)

(4198)

Investor Conference

Peter Lee, COO

December 25, 2020

Disclaimer

- The information contained in this confidential document ("Presentation") has been prepared by S&S Healthcare Holding Ltd. (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.
- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- This Presentation includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.

Content of Report

- Company profile and overview
- Operations Development and Future Prospects
- Q & A

Company profile and overview

Company Profile

Company Name	S&S Healthcare Holding Ltd. (Original name : Swissray Global Healthcare Holding Ltd.)
Company establishment	January 07, 2013
Chairman	Pei-Lin Lee Chairman and GM
Chief Operating Officer	Tien-Ying Lee Director and COO
Chief Financial Officer	Yu-Chun Chen CFO and Head of Accounting
Industry	General investment industry
Business headquarters	Taipei City, Taiwan (R.O.C)

Company summary

Stock code	4198 (TPEX / S&S)
Paid-in capital	NTD 655,400k
Issued ordinary shares	65,540k shares (Including private placement of 23M shares)
2020 Q1~Q3 Operating Revenue	NTD 76,301k
2020 Q3 Total Equity	NTD 91,309k
2019 ROE	-89.45%
Large shareholders	Peter Lee (Shareholding ratio : 36.08%)

Company summary(continue)

Business Scope	Digital X-ray diagnostic imaging equipment and Bone density equipment manufacture, sales, installation, repair, develop and upgrade services for global customers, and maintenance for 1.5T magnetic resonance imaging equipment
Market Positioning	Biotech Medical - Medical Device
Major regional markets	North America 77.84%、 Europe 12.11%、 Asia 10.05%
Main operating proportion	Medical equipment 40.55% Supplies and maintenance 59.45%


Company summary(continue)

Core competencies	Patents, global certification, marketing and customer service network, ability to execute international bids in the United States, Europe and Africa, and visibility of international brand
Number of agents and dealers (As of 2019/12)	12 in Asia、 12 in Europe、 5 in America、 6 in others
Number of employees	31

Memorabilia 2020


2020/03	■ Private placement of 23 million shares
2020/08	■ Company name change: S&S Healthcare (formerly Swissray Global Healthcare)
2020/08	■ Director By-election : 1 seat
2020/09	■ New Subsidiary : Shin Shin Healthcare Co., Ltd.
2020/11	■ Independent Director By-election 1 seat: Huang Muqi Independent Director / Law Specialist

Company Organizational Structure



Operations Development and Future Prospects

Product Lines






ddRAura FMTS



ddRAura OTC (APS)



ddRAura Optix



■ DR- *ddRAura* Series

- *ddRAura* OTC (APS)

Full digitalized ceiling-mounted digital X-ray system with Automatic Position System (APS), auto-tracking function and unique single focus stitching function to support all sorts of clinical studies. *ddRAura* OTC (APS) is the most comprehensive and primum system in digital X-ray industry.

- *ddRAura* FMTS

Full digitalized floor-mounted digital X-ray, easy to use system with auto-tracking function to support all sorts of clinical studies.

- *ddRAura* Optix

Full digitalized manual C-arm digital X-ray system with small foot print, easy to use and support all sorts of clinical studies.

- *ddRAura* Drive Kit

Digital upgrade kit to convert analog or CR X-ray system to a fully digitalized machine.

■ Dual-energy X-ray absorptiometry- Norland DXA Series

- Elite

Premium whole body DXA system dedicated for obesity & sport market.

- XR-800

Whole body DXA system for all sorts of bone density and body composition clinical measurements and researches.

- XR-600

Body part DXA system for all sorts of bone density and body composition clinical measurements and researches.

Operating Strategy

- ◆ First priority: continue to reduce losses and increase cash inflows
 - Net loss reduced from NT\$90.92 million in 2019 to NT\$90.33 million in 2020
- ◆ Expansion of business and product sales bases, increase the source of operating income and coordinate with the operation plan and effectively reduce overall operating expenses.
- ◆ Uphold the value of Swissray and Norland brands in the imaging industry.
- ◆ Resources are actively invested in the ongoing development of ophthalmic optics and new product projects that may be profitable in the short, medium and long term in the development of other medical supplies in the future. For example: Personal Protective Equipment (PPE), namely face masks, protective clothing, medical latex gloves... and other related products.

■ X-ray

- Maintain the Swissray brand, user satisfaction, FDA and CE quality systems with the minimum investment through partnership in production, maintenance and sales business.


■ DXA-

- Transfer partial production capacity to Taiwan to enhance product competitiveness.

Orthro-k Business

- Started the clinical trials in the Tri-Service General Hospital and National Taiwan University Hospital.
- Completed ISO13485 at the Taipei factory.
- Applying the Good Manufacturing Practices (GMP) certification

Outlook: Orthro-k Business



PPE Department

■ Face masks

- factory set up in Changhua, Taiwan with eight production lines completed.
- professionals are recruited for training.
- factory registration, Pharmacist selling license, and Pharmacist manufacturing license granted
- US FDA QKR registered
- CNS-14774 and biocompatibility test passed.
- The EU CE self-declaration application is expected to be obtained early next year
- Form a consultant team to apply for GMP Good Manufacturing Practice certification

Prospects And Operating Policies

Transformation of Medical Imaging Business

- Keep cooperation with supplier chain of existing products
- Build production capacity in Taiwan, actively reduce costs and enhance overall competitiveness
- Product transformation and resource allocation
- Maintain core business and steadily expand new business

From Medical Imaging Device To Healthcare industry

- Expanding service scope from medical imaging business to healthcare industry
- Launching new product lines: PPE
- Developing equipment for long-term care service
- Expanding to veterinary healthcare business

Strengthen Domestic And Global Sales Channels

- Integration of physical and virtual channels
- Expansion of domestic and international distributors
- Introduction of other sales models

Q & A



Thank you for your time.